Antibiotic Concentration in Internal Mammary Graft Preparation
Recruitment status was Recruiting
The negative effect of internal mammary harvesting on sternal perfusion is well known, especially in diabetic subjects. Microdialysis previously showed increased lactate tissue concentration after mammary artery preparation. Although high antibiotic concentration is of utmost importance in this region, no study previously measured the effect of internal mammary artery harvesting on target tissue antibiotic concentration.
Internal mammary artery harvesting imposes an additional risk for deep sternal wound infection by impairing antibiotic tissue penetration. This effect is mediated by altered perfusion patterns and may be seen in cephalosporin and/or Teicoplanin treatment.
To evaluate the impact of left internal mammary artery preparation on target tissue antibiotic concentration of Cefazolin and Teicoplanin during cardiac surgery
This study is designed as an observational pharmacokinetic trial. Patients are their own controls by measuring antibiotic concentration in different subcutaneous tissues.
Patients referred for coronary artery bypass grafting to the Department of Cardiothoracic Surgery with planned unilateral left internal mammary artery preparation and a high risk profile for deep sternal wound infections will be asked to participate in this trial.
Coronary Heart Disease
Surgical Wound Infection
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Target Tissue Concentration of Standard Antibiotic Treatment in Coronary Artery Bypass Grafting Using Left Internal Mammary Artery|
- - Difference of tissue concentration of Teicoplanin between left and right pre-sternal subcutaneous tissue and between the subcutaneous tissue at the tight [ Time Frame: 10 hours ] [ Designated as safety issue: No ]measurement with microdialysis
- - Difference of tissue concentration of Cefazolin between left and right pre-sternal subcutaneous tissue and between the subcutaneous tissue at the tight [ Time Frame: 10 hours ] [ Designated as safety issue: No ]measurement with microdialysis
|Study Start Date:||November 2010|
CABG - subjects
only one group
Please refer to this study by its ClinicalTrials.gov identifier: NCT01324804
|Contact: Martin Andreas, MD, MBAemail@example.com|
|Medical University of Vienna||Recruiting|
|Vienna, Austria, 1090|
|Contact: Martin Andreas, MD, MBA 00431404005262 firstname.lastname@example.org|